COX-2 Inhibitor Drug Review

Supplemental results to the large COX-2 inhibitor review in JAMA: "Adverse Effects of Cyclooxygenase-2 Inhibitors on Renal and Arrhythmia Events: Meta-Analysis of Randomized Trials"

Official supplemental website authorized by the executive editors of Journal of the American Medical Association

Full text of study available via JAMA

Geo-distribution of visitors to COX2DrugReview.Org


Supplemental results for lumiracoxib (PRESTIGE) . Please view the desired forest plots below. Bars represent the upper and lower 95% confidence bounds, X-axis label is "Relative risk".

Note: Lumiracoxib is still undergoing development. Several large trials underway or have been completed but results remain undisclosed. Thus, these results are only considered temporary and tentative, awaiting further data.

[For information on methods and primary results, please see the original article]

Composite Renal

*Other renal sub-endpoint forest plots not shown due to limited number of trials.

Search 'COX-2 Inihibitor Drug Review' Archives Web